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Abstract
Background: Excellent dosimetric characteristics were demonstrated for volumetric modulated arc therapy (VMAT)
in preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). In a single-center retrospective
analysis, we tested whether these advantages may translate into significant clinical benefits. We compared VMAT to
conventional 3D conformal radiotherapy (3DCRT) in patients, homogeneously treated according to the control arm
of the CAO/ARO/AIO-04 trial.
Methods: CRT consisted of pelvic irradiation with 50.4/1.8Gy by VMAT (n = 81) or 3DCRT (n = 107) and two cycles of
5-fluorouracil. Standardized total mesorectal excision surgery was performed within 4–6 weeks. The tumor regression
grading (TRG) was assessed by the Dworak score. Acute and late toxicity were evaluated via the Common Terminology
Criteria for Adverse Events and the Late effects of normal tissues scale, respectively. Side effects greater than or equal
to grade 3 were considered high-grade.
Results: Median follow-up was 18.3 months in the VMAT group and 61.5 months in the 3DCRT group with no
differences in TRG between them (p = 0.1727). VMAT treatment substantially reduced high-grade acute and late
toxicity, with 5 % versus 20 % (p = 0.0081) and 6 % vs. 22 % (p = 0.0039), respectively. With regard to specific organs,
differences were found in skin reaction (p = 0.019) and proctitis (p = 0.0153).
Conclusions: VMAT treatment in preoperative CRT for LARC showed the potential to substantially reduce high-grade
acute and late toxicity. Importantly, we could demonstrate that VMAT irradiation did not impair short-term oncological
results. We conclude, that the reduced toxicity after VMAT irradiation may pave the way for more efficient systemic
therapies, and hopefully improved patient survival in the multimodal treatment of LARC.
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Background
Preoperative chemoradiotherapy (CRT) for locally ad-
vanced rectal cancer (LARC), followed by standardized
total mesorectal excision (TME) surgery, results in excel-
lent local control rates, but distant failure compromises
patients’ survival [1, 2]. To reduce distant failure risk,
clinical trials aim to intensify systemic treatment, at the
hazard of increased toxicity and quality of life impair-
ment [3–5]. Such strategy requires the optimization of
any local therapy, including radiotherapy (RT), in terms
of efficacy and tolerability.
Advanced RT techniques, namely intensity-modulated
radiotherapy (IMRT), volumetric modulated arc therapy
(VMAT), and proton therapy showed excellent target
volume coverage and organs at risk sparing in dosimet-
ric studies [6–8]. To a very limited extent, clinical
studies on LARC irradiation reported enhanced tumor
response [9] and reduced acute toxicity [9, 10] when
IMRT was compared to conventional 3D conformal
radiotherapy (3DCRT). A large-scale direct compari-
son of clinical results after VMAT and 3DCRT has not
been reported to date.
Based on promising dosimetric results, VMAT was
introduced to our clinic and gradually replaced 3DCRT
for LARC since 2009. The purpose of the present single-
center study was to compare VMAT-treated patients
with 3DCRT-treated patients in terms of tumor re-
sponse, acute and late toxicity.
Methods
Patients
The database at our institution contained 188 patients
who were consecutively treated with neoadjuvant CRT
and concurrent 5-fluorouracil for non-metastatic LARC
from 2005 to 2014. The diagnosis was assured via rigid
endoscopy with histologic sampling. The clinical tumor
stage was assessed by endoscopic ultrasound and pelvic
MRI scan.
All patients were treated according to the control arm
of the CAO/ARO/AIO-04 trial [EudraCT no.: 2006-
002385-20]. This multicenter, randomized phase III trial
investigated the addition of oxaliplatin to multimodal
treatment of LARC. Patients were assigned to receive
either standard neoadjuvant 5-fluorouracil-based CRT,
TME surgery, and adjuvant 5-fluorouracil chemotherapy
(control arm), or neoadjuvant CRT with 5-fluorouracil/
oxaliplatin, TME surgery, and adjuvant 5-fluorouracil/
oxaliplatin/leucovorin (investigational arm) [4]. At our
institution, all the LARC patients were highly homoge-
neously treated by a specialized interdisciplinary group
in the context of the Clinical Research Unit 179,
funded by the German Research Foundation (DFG).
The investigations were conducted according to Dec-
laration of Helsinki principles. The Ethics Committee
at the University of Göttingen approved the study, and
patients gave informed consent in written form.
Chemoradiotherapy
RT was applied with linear accelerator photons to a refer-
ence dose of 50.4Gy in 1.8Gy fractions. Patients were posi-
tioned in abdominal position on a belly board. The clinical
target volume (CTV) and the organs at risk were outlined
on the basis of the planning CT scan and the diagnostic
MRI scan, using the Eclipse system (v8.9, Varian Medical
Systems). The CTV included the primary tumor and the
mesorectal, presacral and internal iliac lymph nodes [4].
The planning target volume (PTV) was defined by enlar-
ging the CTV in all directions by 10 mm. Patients were
treated according to respective technical standards. Con-
ventional 3DCRT was used from 2005 to 2012, while
VMAT superseded 3DCRT as of 2009.
The treatment plans were calculated according to ICRU
recommendations. The dose was defined at the ICRU 50
reference point. The isodose curve representing 95 % of
the prescribed dose had to encompass the entire PTV and
the maximum dose to the PTV was limited to <107 %
of the prescribed dose [11, 12]. The aim was to
minimize the dose to the organs at risk, using these
constraints [7]: bladder ≥40Gy in ≤50 % volume; small
bowel ≥50Gy in ≤10 cm3 volume and ≥40Gy in ≤100 cm3
volume, whereas individual loops of small bowel were
contoured.
As described before, the 3DCRT was applied using a
three-field technique. The beam angles were 0, 90 and
270°. The photon energies were 6 MeV (beam direction,
0°) and 20 MeV (beam directions, 90 and 270°). A multi-
leaf collimator (Millennium 120, Varian Medical Systems)
was used to shape the fields. Wedges (45° or 60°) were
used in lateral fields to obtain homogeneous dose distribu-
tion. VMAT was carried out using RapidArc© (Varian
Medical Systems) with two full arcs, and with a photon
energy of 6 MeV. A single arc was arranged into 177 con-
trol points (1 control point about every 2° of gantry) [7].
The concurrent chemotherapy for all patients con-
sisted of 5-fluorouracil (1000 mg/m2 on days 1–5 and
29–33 of the RT). Standardized TME surgery was per-
formed within 4–6 weeks, followed by 4 cycles of bolus
5-fluorouracil (500 mg/m2).
Tumor response/ toxicity assessment
The tumor staging in the resected specimen was based
on the sixth edition of the TNM classification [13]. The
tumor regression grading (TRG) was assessed by the
quantification of the ratio of tumor tissue versus fibrotic
tissue (Dworak score) [14].
Acute toxicity was assessed via the National Cancer In-
stitute Common Terminology Criteria for Adverse Events,
version 3.0 [15]. A minimum of weekly examinations by
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the treating radiation oncologist and weekly blood sam-
ples were mandatory. After CRT, patients were closely
monitored for at least 2 weeks and beyond that in the case
of persisting acute toxicity. Late toxicity was evaluated
according to the Late effects of normal tissues scale [16].
Patients were monitored for late toxicity at 3 months, and
thereafter annually for up to 5 years. Toxicity of ≥ grade 3
was defined as high-grade toxicity.
Statistical analysis
For the comparison of the patient characteristics, tox-
icity, surgery and histopathological parameters, the me-
dian and range are given for the continuous parameters
while frequency and percentage are given for the cat-
egorical variables. The Chi-Square test and the Kruskal-
Wallis test were used for comparison of categorical and
continuous variables. The Kaplan-Meier method was
used to compare the actuarial occurrence of late tox-
icity. P-values <0.05 were considered statistically signifi-




We included 188 patients who were treated from 05/2005
to 01/2014. Patient characteristics are presented in Table 1.
The median patient age was 66 years (range, 35–86 years)
with 64 years (range, 35–83 years) in the 3DCRT group,
and 70 years (range, 43–86 years) in the VMAT group.
The 3DCRT technique was used in 107 (56.9 %) patients
and the VMAT technique in 81 (43.1 %).
There were no differences in clinical T category, clin-
ical N category, tumor grading and tumor distance from
the anal verge. The VMAT group had a significantly
larger proportion of patients with ≥70 years (p = 0.0378)
and with a lower body mass index (p = 0.0453).
Surgery and histopathological parameters
Surgery and histopathological data are presented in
Table 2. The surgical procedures consisted of 123 low
anterior resections (65 %) and 65 abdominoperineal re-
sections (35 %). The frequency of low anterior resections
and abdominoperineal resections was 68 (64 %) and 39
(36 %) in the 3DCRT group and 55 (68 %) and 26 (32 %)
in the VMAT group, respectively. In tumors located
within 0 to <6 cm from the anal verge, sphincter-saving
surgery was performed in 9/40 patients (23 %) of the
3DCRT group and in 11/35 patients (31 %) of the VMAT
group. A complete resection (R0) was achieved in 183
patients (97 %) with 104 (97 %) in the 3DCRT group and
79 (98 %) in the VMAT group. There were no differ-
ences regarding TRG, ypT category and ypN category.
Acute toxicity
Acute organ toxicity data are presented in Table 3. Any
kind of high-grade acute organ toxicity occurred in 25 of
188 patients (13 %), and was more frequent in the
3DCRT group with 21 of 107 patients (20 %) than in the
VMAT group with four of 81 patients (5 %) (p = 0.0081).
The 3DCRT patients had a significantly higher propor-
tion of ≥ grade 3 skin reaction with 7 (7 %) in the
3DCRT group and 0 (0 %) in the VMAT group (p = 0.019).
The frequency of ≥ grade 3 proctitis was higher in the
3DCRT cohort with 13 (12 %) for 3DCRT patients and 2
(2 %) for VMAT patients (p = 0.0153). In multi-group
comparison, any kind of acute organ toxicity (p = 0.0113)






No. % No. %
Gender
female 30 28 23 28 0.9570
male 77 72 58 72
Age, years
≥70 years 38 36 41 51 0.0378
<70 years 69 64 40 49
Body mass index [kg/m2]
<20 2 2 0 0 0.0453
20–24.9 32 30 24 30
25–26.9 15 14 19 24
27–29.9 27 25 27 33
≥30 31 29 11 13
Clinical T category
2 2 2 2 3 0.7843
3 96 90 70 86
4 9 8 9 11
Clinical N category
negative 29 27 18 22 0.4441
positive 78 73 63 78
Grading
X 9 8 14 17 0.0806
1 1 1 0 0
2 75 70 60 74
3 21 20 7 9
4 1 1 0 0
Distance from anal verge
0 to <6 cm 40 37 35 43 0.7212
6 to <12 cm 64 60 44 54
12 to 16 cm 3 3 2 3
The Chi-Square test and the Krusal-Wallis test were used for group comparisons
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and the skin reaction (p = 0.0056) were significantly more
frequent in the 3DCRT group.
Any kind of hematotoxicity (anemia, leucopenia, throm-
bopenia) ≥ grade 3 occurred in six patients (3 %) with four
patients (4 %) in the 3DCRT group and two patients (3 %)
in the VMAT group. The 3DCRT and VMAT group
comparison showed no differences regarding hematotoxi-
city (Additional file 1: Table S1).
Late toxicity
Late toxicity data are presented in Table 4. Follow-up
data were available for 173 patients (92 %) with 102
patients (95 %) in the 3DCRT group and 71 patients
(88 %) in the VMAT group. The median follow-up time
was 61.5 months (range, 4.0–105.7 months) in the
3DCRT group and 18.3 months (range, 4.0-59.2 months)
in the VMAT group. The 2-year rates of freedom from
high-grade late organ toxicity were 81 % for the 3DCRT
group and 91 % for the VMAT group (Fig. 1). There
were no differences regarding skin toxicity, proctitis







No. % No. %
OP-method
Low anterior resection 68 64 55 68 0.5356
Abdominoperineal resection 39 36 26 32
Distance from anal verge 0 to <6 cm, sphincter-saving surgery
Yes 9 23 11 31 0.3830
No 31 77 24 69
R-status
0 104 97 79 98 0.5330
1 1 1 2 2
2 1 1 0 0
X 1 1 0 0
ypT-stage
0 14 13 16 20 0.1397
1 11 10 5 6
2 34 32 25 31
3 42 39 35 43
4 6 6 0 0
ypN-stage
0 69 65 57 70 0.5492
1 27 25 15 19
2 11 10 9 11
Tumor regression grading
0 no regression 0 0 1 1 0.1727
1 minor regression 12 11 9 11
2 moderate regression 34 32 32 40
3 good regression 47 44 23 28
4 total regression 14 13 16 20
The Chi-Square test and the Krusal-Wallis test were used for group comparisons
Abbreviations: R-status resection status, ypT tumor stage after preoperative
radiochemotherapy, ypN nodal stage after preoperative radiochemotherapy








No. % No. % Chi-square, p Kruskal-Wallis, p
Skin reaction
≥3 7 7 0 0 0.0190
0 21 20 26 32 0.0056
1 42 39 39 48
2 37 34 16 20
3 7 7 0 0
Proctitis
≥3 13 12 2 2 0.0153
0 15 14 9 11 0.0670
1 36 34 36 45
2 43 40 34 42
3 13 12 2 2
Enteritis
≥3 4 4 1 1 0.2907
0 53 49 36 44 0.5898
1 34 32 29 36
2 16 15 15 19
3 4 4 1 1
Cystitis
≥3 3 3 1 1 0.4603
0 63 59 39 48 0.2219
1 39 36 35 43
2 2 2 6 7
3 2 2 1 1
4 1 1 0 0
Balanitis
0 106 99 81 100 b
3 1 1 0 0
Any kind of acute organ toxicitya
≥3 21 20 4 5 0.0081
0 4 4 2 3 0.0113
1 27 25 36 44
2 55 51 39 48
3 20 19 4 5
4 1 1 0 0
aThe highest score of any acute organ toxicity per patient
bNo statistical comparisons due to small groups of patients
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and cystitis. Additional high-grade toxicity, namely
enteritis (n = 4), urethral stricture (n = 1) or ureteral
stenosis (n = 5) occurred in 10 3DCRT patients (10 %),
while none of the VMAT patients (0 %) experienced
these complications. Any kind of high-grade late organ
toxicity occurred in 26 patients (15 %) with 22 patients
(22 %) in the 3DCRT group and four patients (6 %) in
the VMAT group (p = 0.0039). In multi-group compari-
son, high-grade late organ toxicity was significantly
more frequent in the 3DCRT group (p = 0.0073).
Discussion
The use of IMRT and VMAT in the preoperative CRT of
LARC is still rare, but dosimetric studies showed excel-
lent target volume coverage and organs at risk sparing
[7, 8, 10, 17]. Our group already demonstrated the
superiority of VMAT over 3DCRT in a planning study
with 25 patients, using the treatment protocol of the
current study [7]. We analysed, whether these dosimetric
advantages translate into significant clinical benefits.
When directly comparing VMAT-treated patients with
3DCRT-treated patients in terms of tumor response,
acute and late toxicity we found that VMAT provides
equal tumor regression combined with reduced acute
and late organ toxicity.
To assess tumor response, we used the standardized
five-point TRG [14], and found no differences between
VMAT-treated patients and 3DCRT-treated patients.
Fokas et al. identified TRG as an independent prognostic
factor for metastasis-free and disease-free survival of
LARC patients treated according to the protocols of the
CAO/ARO/AIO rectal cancer trials [18]. Thus TRG may
reflect CRT effectiveness and our data could indicate
that VMAT-treated patients will experience satisfying
oncological outcome. This assumption is supported by a
small feasibility study [6], where Richetti et al. analysed
VMAT in 45 patients with preoperative CRT of LARC
and demonstrated improved dose conformality and a
tumor downstaging, comparable to previously published
data for conventional RT. Furthermore the favorable
oncological outcome in patients treated with IMRT for
rectal cancer [9, 19] and other tumors [20–23] supports
a potential benefit for VMAT-treated patients. IMRT
and VMAT have comparable dosimetric characteristics
[17], but IMRT is already used for quite some time and
therefore patient data with longer follow up periods are
available [24].
In addition, for IMRT, an excellent toxicity profile was
achieved for patients with LARC [9, 10, 25], and other
tumor entities [20–23, 26]. Comparisons of IMRT with
3DCRT indicate a reduction of acute gastrointestinal
toxicity and treatment breaks [10, 25]. Since the issue
has not been addressed in larger cohorts, an ongoing







No. % No. % Chi-square, p Kruskal-
Wallis, p
Skin
≥3 2 2 0 0 0.2353
0 83 81 64 90 0.3161
1 16 16 7 10
2 1 1 0 0
3 2 2 0 0
Proctitis
≥3 8 8 2 3 0.1635
0 69 68 52 73 0.2498
1 11 11 10 14
2 14 14 7 10
3 6 6 0 0
4 2 2 2 3
Cystitis
≥3 10 10 2 3 0.0752
0 82 80 65 91 0.2271
1 8 8 2 3
2 2 2 2 3
3 9 9 2 3
4 1 1 0 0
Enteritis
0 96 94 71 100 b
1 2 2 0 0
2 3 3 0 0
3 1 1 0 0
Lymphedema
0 101 99 71 100 b
1 1 1 0 0
Urethral stricture
0 101 99 71 100 b
3 1 1 0 0
Ureteral stenosis
0 97 95 71 100 b
3 5 5 0 0
Any kind of the organ toxicitya
≥3 22 22 4 6 0.0039
0 44 43 47 66 0.0073
1 25 25 12 17
2 11 11 8 11
3 19 19 2 3
4 3 3 2 3
aThe highest score of any late organ toxicity per patient
bNo statistical comparisons due to small groups of patients
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clinical trial aims to compare the acute toxicity rates
after IMRT and 3DCRT [NCT02151019]. Considerable
differences exist between IMRT and VMAT, namely the
reduction of treatment delivery time and the number of
applied monitor units [6, 27]. Thus, the clinical compari-
son of VMAT and 3DCRT must be addressed separately.
In general, clinical toxicity data for VMAT are scarce. A
favorable acute toxicity profile was described for pros-
tate, non-small cell lung, anal canal and endometrial
cancer [28–31], and in the feasibility study of Richetti et
al. for LARC [6], where high-grade acute organ toxicity
occurred in three patients (7 %), only.
The current study demonstrates the potential of
VMAT to substantially reduce high-grade acute organ
toxicity, showing a ratio of 20 % for 3DCRT versus 5 %
for VMAT. Well-known risk factors for the occurrence
of high-grade acute organ toxicity in preoperative CRT
of LARC are female gender [32], age ≥70 years [33] and
low body mass index [34]. In the current study, the
VMAT group showed a significantly higher proportion
of patients being older than 70 years and having a low
body mass index. Remarkably, the VMAT treatment re-
sulted in lower acute toxicity rates despite the prepon-
derance of features for higher risk of toxicity.
With regard to specific organs, differences were found
in high-grade skin reaction (7 % vs. 0 %) and in proctitis
(12 % vs. 2 %). The reduction of skin reaction might be
explained by the fact that VMAT treatment generally
leads to an increase in the volume of normal tissue
receiving low-dose irradiation and to a decrease in the
volume of normal tissue receiving high-dose irradiation
[27]. For IMRT in breast cancer treatment, a reduction
in acute skin reaction in comparison to 3DCRT was
demonstrated [35] where moist desquamation likely oc-
curred in highest skin dose areas [36]. The reduction in
proctitis rates was not described previously in the lit-
erature. Our group already demonstrated a significant
reduction of high dose areas in the PTV with VMAT
plans (V107 % = 0.1 %) in comparison to 3DCRT plans
(V107 % = 3.5 %) [7]. The diminution of rectal high-dose
areas could lead to lower rates of injury to the rectal wall.
In the current study, no differences between 3DCRT
treatment and VMAT treatment were observed regard-
ing hematotoxicity. Altogether, six patients (3 %) devel-
oped high-grade hematotoxicity. Mell et al. found the
irradiated volume of pelvic bone marrow receiving low-
dose irradiation to be predictive for hematotoxicity in
the CRT of cervical cancer with IMRT. The authors
Fig. 1 Freedom from ≥ grade 3 late toxicity. The Kaplan-Meier method was used to compare the occurrence of late toxicity in patients who
underwent neoadjuvant chemoradiotherapy (CRT) with 3D conformal radiotherapy (3DCRT) or volumetric modulated arc therapy (VMAT)
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argued that the use of IMRT might be suitable to
reduce hematotoxicity in pelvic RT [37]. However, there
are no available data comparing hematotoxicity after
3DCRT and VMAT in a similar patient population. Our
findings suggest that, despite the probable increase in
irradiated volume of bone marrow with VMAT in
comparison to 3DCRT, there is no clinically detectable
negative effect on hematotoxicity.
To our knowledge, no published data exist on the late
toxicity rates after VMAT in preoperative CRT for
rectal cancer. We found significantly lower rates of late
toxicity for VMAT in comparison to 3DCRT. High-
grade late organ toxicity occurred in 22 % of the
3DCRT patients and in 6 % of the VMAT patients.
Altogether, high-grade enteritis, urethral stricture or
ureteral stenosis occurred in 10 % of the 3DCRT pa-
tients, while none of the VMAT patients experienced
these complications. In general, the small bowel and
bladder complications occur after organ exposure to
RT doses of ≥50Gy [38]. Especially for comparably high
dose levels, our group demonstrated a remarkable
improvement with VMAT. For the small bowel, the
V40Gy was 28.4 % with VMAT plans and 41.8 % with
3DCRT plans. For the urinary bladder, the V40Gy was
66.5 % with VMAT plans and 88.4 % with 3DCRT plans
[7]. These findings could explain the absence of enter-
itis, urethral stricture and ureteral stenosis in VMAT
patients.
To address the limitations of the current study,
though patients were treated in accordance with the re-
spective protocol, the comparison of 3DCRT and
VMAT was not a predefined endpoint of the trial.
Thus, a potential bias due to covariates cannot be ex-
cluded with absolute certainty. Furthermore, due to the
fact that VMAT was introduced into clinical practice
only a short time ago, the groups appear different in
length of follow-up. As an important concern for the
late toxicity data, a prolonged observation period is re-
quired. However, the latency to the occurrence of late
toxicity in preoperative CRT of LARC is less well
known. After RT of cervical cancer, high rates of urin-
ary tract and small bowel complications were found
during earlier follow-up. The complication rates sharply
declined after 2–3 years [39]. In the current study, 28
patients (35 %) in the VMAT group were observed for a
period of >2 years. Since none of these patients experi-
enced high-grade enteritis, urethral stricture or ureteral
stenosis, the current findings indicate that VMAT re-
duces late toxicity in preoperative CRT of LARC.
Nevertheless, the outstanding strength of the current
study is the homogeneous treatment according to the
German CAO/ARO/AIO-04 trial. The presented data
highlight the benefits of the VMAT irradiation for
LARC on a powerful basis.
Conclusions
In summary, VMAT treatment in preoperative CRT for
LARC showed the potential to substantially reduce
high-grade organ toxicity, and lower rates of late tox-
icity were conceivable. Importantly, we could demon-
strate that VMAT irradiation did not impair short-term
oncological results. We conclude, that the delivery of
preoperative RT using VMAT may pave the way for
more efficient systemic therapies, and improved patient
survival in the multimodal treatment of LARC.
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